AIDSVAX B/E
AIDSVAX B/E is a biological therapy with 9 clinical trials. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
4 of 6 finished
33.3%
2 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
Clinical Trials (9)
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
Study of Immune Responses Induced by a HIV Vaccine
Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults
All 9 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 9